SACRAMENTO - More than 17 people claim Eli Lilly failed to warn of the frequency and severity of withdrawal symptoms from Cymbalta, a selective serotonin reuptake inhibitor it introduced when it lost its patent on Prozac, in Federal Court.
Categories / Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.
Additional Reads
-
-
Texans head to the polls for high-stakes US Senate primary February 17, 2026